

# Visegrad research meeting

Under the auspices  
of Czech Myeloma Group

Wednesday

# 20. 3. 2024

Clarion Congress  
Hotel Ostrava,  
meeting room Platinum

Chairmans: R. Hájek,

Visegrad Symposium is project of Czech Myeloma Group. It provides a platform for international communication in the management of patients with monoclonal gammopathies. This year, in 2024, is symposium focused on the update of research and clinical activities of cell therapy and immunomonitoring.

16:45 – 17:00 Roman Hájek (Ostrava)

**Welcome reception**

## PART I: Hematologic malignancies

17:00 – 17:10 Artur Jurczyszyn (Kraków)

**Real-world analysis of teclistamab in RRMM patients**

17:10 – 17:25 Tereza Popková, Tereza Ševčíková (Ostrava)

**CMG activity – 2024 Update**

17:30 – 17:40 Gabor Mikala (Budapest)

**High sensitivity droplet digital RT-PCR monitoring of t(4;14) translocated myeloma**

17:40 – 17:50 Zoltán Kellermayer (Pécs)

**Bone marrow adipocytes in the bone marrow niche**

17:50 – 18:05 Dominik Dytfeld (Poznań)

**ATLAS and COBRA studies – 2024 Update**

18:05 – 18:15 Varga Gergely (Budapest)

**TBD**

## 10 min COFFEE BREAK

## PART II: Cell Therapies & Immuno-monitoring

18:25 – 18:40 Jan Vydra (Praha)

**Upcoming Phase I Trial of CD123-CAR for R/R AML and MDS**

18:40 – 18:55 Sebastian Giebel (Gliwice)

**Access to CAR-T in Poland & CAR-NET – 2024 Update**

18:55 – 19:05 Piotr Cielichowski, Michal Šimíček (Ostrava)

**Development of CAR-T cells in Ostrava – 2024 Update**

19:05 – 19:15 Tomáš Kríž (Plzeň)

**Clinical trial using invariant NKT cells for the treatment of GvHD**

19:15 – 19:30 Samo Zver (Ljubljana)

**Cell therapy clinical and research moment of hematology in Slovenija**

19:30 – 19:45 Jan Frič (Brno)

**TGF- $\beta$  role in NK cells migration and cytotoxic efficiency in complex models of leukemia microenvironment**

19:45 – 20:00 Roman Hájek, Jana Mihályová, Ondřej Venglář (Ostrava)

**Project “Immunomonitoring”**

## PART III: Discussion – potential cooperative projects

20:00 +